All data are based on the daily closing price as of July 12, 2024
p

Pharmicell

005690.KO
4.04 USD
0.07
+1.76%

Overview

Last close
4.04 usd
Market cap
242.48M usd
52 week high
8.19 usd
52 week low
3.88 usd
Target price
12.74 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
14.2587
Price/Book Value
4.2467
Enterprise Value
184.28M usd
EV/Revenue
5.8766
EV/EBITDA
39.1483

Key financials

Revenue TTM
17.43M usd
Gross Profit TTM
6.32M usd
EBITDA TTM
-4.50M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
69.06M usd
Net debt
N/A usd

About

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; Hearticellgram_AMI, a cardiac disease drug; Cellgram_CKD for the treatment of chronic kidney disease; and Cellgram_AKI for the treatment of acute kidney disease. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, as well as clinical development and commercialization services for new drugs. Further, it operates Twelve, a stem cell bank; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
  • Symbol
    005690.KO
  • Exchange
    KO
  • Isin
    KR7005690003
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    Seoul
  • Web site
    https://www.pharmicell.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top